Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + bortezomib + rituximab + CHOP in elderly patients with CD20-positive diffuse large B-cell lymphoma
2015-003429-32Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib, bortezomib, rituximab, cyclophosphamide, doxorubicin and 2 more in diffuse large B-cell lymphoma (DLBCL) and mature B-cell lymphoma, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: 2-year progression-free survival. Started Aug 2016; status: completed.
02
Drugs
ibrutinibbortezomibrituximabcyclophosphamidedoxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2015-003429-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003429-32.